357 filings
Page 3 of 18
8-K
mht2qpgzqy
10 May 21
ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results
6:36am
8-K
uueganwt6js1enhcjkz
12 Feb 21
Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End
6:37am
8-K
vyphn qqwzqoa
11 Jan 21
Results of Operations and Financial Condition
7:01am
8-K
plxb7qsmjj6n1ci
18 Dec 20
Entry into a Material Definitive Agreement
5:19pm
8-K
3fudse1qyqakxva
18 Dec 20
Other Events
4:16pm
8-K
huh90f 2ck8o72i65x2y
11 Dec 20
Other Events
4:40pm
8-K
s5op0qt8qyw2j7m
7 Dec 20
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
8:02am
8-K
hdneyp
6 Nov 20
ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results
6:53am
8-K
meiq87d9
26 Oct 20
Departure of Directors or Certain Officers
9:22am
8-K
p8l1663
19 Oct 20
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
8:57am
8-K
dugh 80dgekdrha
13 Oct 20
Other Events
8:11am
8-K
2nf6imwq
25 Sep 20
Entry into a Material Definitive Agreement
4:38pm
8-K
c3o5umj6w5b4fonuwj80
31 Jul 20
ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results
8:41am
8-K
b9hcoo7
22 Jul 20
ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer
4:10pm
8-K
3ww0u7tso4 5vu
2 Jul 20
Departure of Directors or Certain Officers
4:16pm
8-K
81aa8d 3pgqt6ne
18 Jun 20
Submission of Matters to a Vote of Security Holders
8:15am
8-K
zz0bddbo2r 7f
1 May 20
ImmunoGen Reports Recent Progress and First Quarter 2020 Financial Results
6:35am
8-K
8ijgcqe34iswsdsk py
14 Feb 20
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:46pm
8-K
642vfe7g1pygv
14 Feb 20
ImmunoGen Reports Recent Progress and 2019 Financial Results
6:36am
8-K
njy o7br88
27 Jan 20
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:13pm